Эндокринная офтальмопатия: диагностика, особенности течения после радиойодтерапии болезни Грейвса
Диссертация
Апробация диссертации состоялась на межотделенченской научной конференции в ФГУ Эндокринологический научный центр 17 февраля 2010 года. Результаты исследования были представлены в виде устных докладов на Научно-практической нейроофтальмологической конференции «Актуальные вопросы нейроофтальмологии» (Москва, 25 января 2008.), Всероссийской научно-практической конференции молодых ученых… Читать ещё >
Список литературы
- Бровкина А.Ф. // Эндокринная офтальмопатия. М.: ГЕОТАР -МЕД. -2004—С.39−40.
- Бровкина А. Ф, Яценко О. Ю, Аубакирова А. С. КТ-признаки изменений экстраокулярных мыпщ при эндокринной офтальмопатии // Вестник офтальмологии—2006-№ 6-С. 17−19.
- Бровкина А. Ф, Яценко О. Ю, Аубакирова А. С. Компьютерно-томографическая анатомия орбиты с позиции клинициста // Вестник офтальмологии —2008—№ 1—С.11−14.
- Бровкина А.Ф., Павлова T.JI. Эндокринная офтальмопатия с позиции офтальмолога и эндокринолога // Клиническая офтальмология — 2000- № 1-С. 11- 14.
- Вальский В.В. Особенности компьютерно-томографической диагностики эндокринной офтальмопатии.// Опухоли и опухолиподобные заболевания органа зрения -1998-С.136—138.
- Вальский В.В. Компьютерная томография в диагностике планирования и оценке эффективности лечения заболеваний органа зрения: Дис. .д-ра мед. наук. -1998-С. 136−138.
- Гарбузов П.И., Дроздовский Б. Я., Родичев А. А., и др. Радиойодтерапия рака щитовидной железы // Практическая онкология. 2007.- Т.8, № 1. — С. 42−45.
- Герасимов Г. А., Мельниченко Г. А., Петунина Н. А., Федак И. Р. Современные представления о лечении тиреотоксикоза радиоактивным йодом. Комментарии к рекомендациям европейских экспертов// Проблемы эндокринологии.- 1997.-№ 1 .-С.28−31.
- Дедов В.И., Дедов И. И., Степаненко В. Ф. //Радиационная эндокринология. М., 1993. -С.76 —89
- Ю.Ильин JI. А. //Радиационная медицина. -2002. Т. 3. — С. 31−46.
- П.Пантелеева О. Г., Вальский В .В., Тинпсова А. П. Роль компьютерной томографии в диагностике латентной стадии оптической нейропатии при эндокринной офтальмопатии // Современные методы лучевой диагностики в офтальмологии. — 2004— С.219−221.
- Свириденко Н.Ю. Радиойодтерапия //Эндокринология. Национальное руководство/под ред.И.И Дедова, Г. А. Мельниченко. М.: ГЕОТАР -МЕД. — 2008-С. 308−318.
- Фадеев В.В. Болезнь Грейвса // Русский медицинский журнал. 2002.- Т. 10, N 27 (171). — С. 1262 — 1265.
- Фадеев В.В., Дроздовский Б. Я., Гусева Т. Н. и др. Отдаленные результаты лечения токсического зоба радиоактивным 1311 // Проблемы эндокринологии. 2005. — Т.51, № 1. — С.3−10.
- Фадеев В.В. Диагностика и лечение токсического зоба // Русский медицинский журнал. -2002. -Т.Ю, № 11(155).-С. 513−516.
- Цыб А.Ф., Будагов Р. С., Замулаева И. А. // Радиация и патология. —2005. — С. 341.
- Aizawa Y, Yoshida К, Kaise N, Fukazawa H, Kiso Y, Mori К et al. Long-term effects of radioiodine on thyrotrophin receptor antibodies in Graves' disease //Clinical Endocrinology-1995-Vol. 4-P. 517−522.
- Aron-Rosa D, Perez R & Abitbol Y. Malignant exophthalmos after iodine-131 treatment//Modern Problems in Ophthalmology-1975-Vol. 14-P. 432−434.
- Alexander EK, Larsen PR. High Dose 1311 Therapy for the Treatment of Hyperthyroidism Caused by Graves' Disease //J. Clin. Endocrinol. Metab. -2002—Vol. 87—P.1073—1077.
- Bartalena L, Marcocci С & Pinchera A. Radioiodine therapy and Graves' opthalmopathy. In Graves' Disease Pathogenesis and Treatment //Eds. B. Rapoport & SM McLachlan. Boston: Kluwer Academic Publishers-2000- P. 279−288.
- Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell’Unto E, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy//N. Engl. J. Med -1998(a) -Vol. 338-P.73−8.
- Bartalena L, Marcocci C, Tanda ML, Manetti L, Dell’Unto E, Bartolomei MP, et al. Cigarette smoking and treatment outcomes in Graves ophthalmopathy //Ann. Intern. Med. -1998(b) -Vol. 129-P. 632−5.
- Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism //N. Engl. J. Med. -1989-Vol. 321(20) -P.1349−52.
- Bartalena L., Bogazzi F., Tanda M. et al. Cigarette smoking and thyroid // Eur. J. Endocrinol. -1995-Vol. 133-P. 507−512.
- Bartley G. The epidemiology characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease // Trans. Am. Ophthalmol. Soc. 1994 -Vol.92- P.477- 588.
- Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA, et al. The incidence of Graves' ophthalmopathy in Olmsted County, Minnesota//Am. J. Ophthalmol. 1995- Vol.120 (4) — P.511- 7.
- Barth A, Probst P, Burgi H. Identification of a subgroup of Graves' disease patients at higher risk for severe ophthalmopathy after radioiodine //J. Endocrinol. Invest. -1989-Vol. 14(3) -P. 209−12.
- Barrett L., Glat HJ, Burde RM, Gado MH. Optic nerve dysfunction in thyroid eye disease //CT Radiology — 1988 — Vol. 167 — P. 503−507
- Bahn RS, Gorman CA: Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy. // Endocrinol. Metab.Clin. N. Am. -1987. -Vol.16. P.391−407.
- Bahn RS, Heufelder AE. Pathogenesis of Graves' ophthalmopathy //N. Engl. J. Med. 1993- Vol. 329- P. 1468−1475.
- Bahn RS. TSH receptor expression in orbital tissue and its role in the pathogenesis of Graves' ophthalmopathy//!. Endocrinol. Invest. —2004-Vol.27— P. 216−220.
- Веп Simon G.J., Syed H.M., Douglas R., McCann J.D., Goldberg R.A. Extraocular muscle enlargement with tendon involvement in thyroid-associated orbitopathy// Am.J. Ophthalmol.-2004-Vol.l37-N. 6-P.l 145−1147.
- Birchall D, Goodal KL, Noble JL, Jackson A. Graves ophtalmopathy: intracranial fat prolapse on CT images as an indicator of optic nerve compression // Radiology 1996 — Vol.200 — P. 123−127
- Bonnema S J, Bartalenal L, Toft A D and Hegedus L. Controversies in radioiodine therapy: relation to ophthalmopathy, the possible radioprotective effect of antithyroid drugs, and use in large goiters //European Journal of Endocrinology-2002—P. 1471−11
- Burch HB, Wartofsky L. Graves' ophthalmopathy: current concepts regarding pathogenesis and management Endocr. Rev. —1993-Vol.l4—P. 747−793.
- Cawood T, Moriarty P and O’Shea D. Recent developments in thyroid eye disease//BMJ -2004-Vol.329-P. 385−390.
- Casper DS, Chi TL & Trokel SL. Orbital disease, imaging and analysis -Stuttgart //Thieme-1993.
- Crooks J, Buchanan WW, Wayne EJ & MacDonald E. Effect of pretreatment with methylthiouracil on results of 1311 therapy//British Medical Journal -1960—Vol. 1-P.151—154.
- Cooper DS. Hyperthyroidism//Lancet-2003-Vol. 362-P. 459−468.
- DeGroof L., Mangklabrukes A., McCormick M. Comparison of RA-131 I treatment protocols for Graves' disease // J. Endocrinol. Invest. -1990- Vol. 13-P.lll—118.
- Einhorn J & Saterborg N-E. Antithyroid drugs in iodine-131 therapy of hyperthyroidism//Acta Radiologica— 1962-Vol. 58-P.161−167.
- Eckstein A., Quadbeck В., Mueller G. et al. Impact of smoking of the response to treatment of thyroid associated ophthalmopathy // Br. J Ophthalmol. 2003-Vol. 87-N.6-P.773−776.51 .Farid NR, MargaM. //J.Endocrinol. Invest. -2003-Vol.26-P. 570−4.
- Faciani J, Kazim M. Absence of seasonal variation in Graves' disease // Ophthalmol. Plast. Reconstr. Surg. -2000-Vol.l6. -N. 1 P.67−71.
- Fenzi GF, Hashizume K, Roudebush С & DeGroot LJ. Changes in thyroid-stimulating immunoglobulins during antithyroid therapy //Journal of Clinical Endocrinology and Metabolism-1979-Vol. 48-P. 572−576.
- Fernandez-Sanchez JR, Rosell Pradas J, Carazo Martinez O, Torres, Vela E, Escobar Jimenez F, Garbin Fuentes L et al. Graves’ophthalmopathy after subtotal thyroidectomy and radioiodine therapy //British Journal of Surgery — 1993-Vol. 80-P.l 134−1136.
- Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J & Boyle P. Mortality after the treatment of hyperthyroidism with radioactive iodine//New England Journal of Medicine-1998-Vol. 338 -P. 712−718.
- Feldon SE, Weiner JM. Clinical significance of extraocular muscle volumes in Graves' ophthalmopathy: a quantitative computed tomography study//Arch Ophthalmol. 1982 — Vol. 100 — P. 1266−1269
- Feldon SE, Lee CP, Muramatsu SK, Weiner JM. Quantitative computed tomography of Graves' ophthalmopathy: extraocular muscle and orbital fat in development of optic neuropathy // Arch Ophthalmol — 1985 — Vol. 103 — P. 213−215
- Feldon SE, Muramatsu SK, Weiner JM. Clinical classification of Graves' ophthalmopathy: identification of risk factors, for optic neuropathy //Arch Ophthalmol. 1984 — Vol.102 — P. 1469−1472
- Forbes G, Gorman CA, Gehring D & Baker HL. Computer analysis of orbital fat and muscle volumes in Graves' ophthalmopathy//American Journal of Neuroradiology -1983 Vol. 4 — P. 737−742.
- Forbes G, Gehring DG, Gorman CA, Brennan MD & Jackson IT. Volume measurements of normal orbital structures by computed tomographic analysis// American Journal of Neuroradiology —1985-Vol. 6-P. 419−424.
- Forbes G, Gorman С A & Brennan MD. Ophthalmopathy of Graves' disease: computerized volume measurements of orbital fat and muscle// American Journal of Neuroradiology—1986 — Vol. 7-P.651−656.
- Forssberg A. On the possibility of protecting the living organism against roentgen rays by chemical means//Acta Radiologica— 1950-Vol. 33-P. 296— 304.
- Franklyn JA, Daykin J, Drolc Z, Farmer M, Sheppard MC Long-term follow-up of treatment of thyrotoxicosis by three different methods. Clin. Endocrinol. (Oxf)-1991-Vol. 34—P.71—76
- Gerding MN, Terwee CB, Dekker FW, Koornneef L, Prummel MF, Wiersinga WM. Quality of life in patients with Graves' ophthalmopathy is markedly decreased: measurement by the Medical Outcomes Study Instrument// Thyroid— 1997—Vol. 7-P.885−889
- Gorman CA. Therapeutic controversies. Radioiodine therapy does not aggravate Graves' ophthalmopathy //Journal of Clinical Endocrinology and Metabolism-1995—Vol. 80-P.340−342.
- Gorman CA. The measurement of change in Graves' ophthalmopathy// Thyroid -1998 Vol. 8-P. 539−543.
- Hadj-Kacem H., Ballassoned M., Bougacha-Elleuch N. et al. CTLA 4 gene polymorphism in Tunisian patients with Graves' disease // Clin. Immunol. -2001-Vol. 101, No. 3. P. 361−365.
- Hamilton HE, Schutz RO & Gowil EL. The endocrine eye lesion in hyperthyroidism//Archives of Internal Medicine- 1960-Vol. 105-P. 675−685.
- Hatten MP Rubin PA. The pathophysiology of thyroidassociated ophthalmopathy // Ophthalmol. Clin. North Am.- 2002 Vol. 15 — P. 113−119.
- Heufelder A., Joba W. Thyroid-associated eye disease // Strabismus— 2000-N. 2-P.101−111
- Herzen C. Hyperthyreoidose — Differenzial Diagnose. Therapie // Schweiz. Rundsch. Med. Prax. 2003- Vol. 92- N. 1- 2- P.18- 24.
- Hetzel BS, Mason EK & Kwan WH. Studies of serum long-acting thyroid stimulator (LATS) in relation to exophthalmos after therapy for thyrotoxicosis //Australasian Annals of Medicine -1967-Vol. 17-P.307−311.
- Jones В., Kwok L, Kung A. Changes in cytokine production durinj pregnancy in patients with Graves' disease // Thyroid-2000-Vol. 10-N.8-P.701−707.
- Karadimas P., Bouzas E., Mastoranos G. Advice against smoking is not effective in patients with Graves' ophthalmopathy // Acta Mec Austriaca. -2003—Vol.30-N. 2-P. 59−60.
- Kaplan MM, Meier DA, Dworkin Щ Treatment of hyperthyroidism with radioactive iodine/ZEndocrinol. Metab. Clin. North Am. -1998-Vol.27-P. 205 223
- Kahaly GJ. Imaging in thyroid-associatsd orbitopathy// European Journal of Ophthalmology-2001 Vol.145 -P. 107−118
- Kendall-Taylor P, Perros P. Clinical presentation of thyroid associated orbitopathy//Thyroid. 1998- Vol. 8- P. 427- 428.
- Kung AWC, Yau CC & Cheng A. The incidence of ophthalmopathy after radioiodine therapy for Graves' disease: prognostic factors and the role of methimazole//Journal of Clinical Endocrinology and Metabolism -1994 -Vol.79-P. 542−546.
- Kennerdell JS, Rosenbaum AE, El-Hoshy MH. Apical optic nerve compression of dysthyroid optic neuropathy on computed tomography — 1981 — Vol.99 P. 807−809
- Kriss JP, Pleshakov V, Rosenblum AL, Holderness M, Sharp G & Utiger RD. Studies on the pathogenesis of the ophthalmopathy of Graves' disease// Journal of Clinical Endocrinology and Metabolism-1967-Vol. 27-P. 582−593.
- Larsen PR. Thyroidal triiodothyronine and thyroxine in Graves' disease: correlation with presurgical treatment, thyroid status and iodine content// Journal of Clinical Endocrinology and Metabolism —1975-Vol. 41—P. 10 981 104.
- Lowdell CP, Dobbs HJ, Spathis GS, McCready VR et al. Low-dose 1311 in treatment of Graves' disease// J. R. Soc. Med. -1985-Vol. 78-P.197−202
- Lind P. Die ablative therapie der immunhyperthyreose unter spezieller Berucksientigung der endokxinen orbitopathie // Acta Med. Austriaca. — 2000-Vol. 28—N.4-P.105- 107.
- Manso PG., Furlanetto RP., Wolosker AM., Paiva ER., de Abreu MT., Maciel RM. Prospective and controlled study of ophthalmopathy after radioiodine therapy for Graves' hyperthyroidism //Thyroid-1998-Vol. 8(1) -P.49−52.
- Marcocci C., Batalena L., Pinchera A. Recent progress in Graves' ophthalmopathy // Curr. Opin. Endocrinol. Metab. 1996. — N3. — P. 417−422.
- Metcalfe R., Weetman A. Simulation of extraocular muscle fibroblasts by cytokines and hypoxia: possible role in thyroid-associated ophthalmopathy // Clin. Endocrinol. (Oxf.) -1994-Vol.40-P. 67−72.
- McKeag D., Lane C., Lazarus JH., Baldes
- Mourits MP, Prummel MF, Wiersinga WM & Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. //Clin. Endocrinol.(Oxford) — 1997-Vol. 47-P. 9−14.
- Mole RH, Philpot JST & Hodges GRV. Reduction in lethal effect of X-radiation by pretreatment with thiourea or sodium ethane dithiophosphonate// Nature-1950-P. 166−515.
- Muller-Forell W, Pitz S, Mann W & Kahaly GJ. Neuroradiological diagnosis of thyroid-associated orbitopathy //Experimental Clinical Endocrinology Diabetes -1999-Vol.107-P. 177−183
- Neigel JM, Rootman J, Belkin RI, Nugent RA, Drance SM, Beattie GW et al. Dysthyroid optic neuropathy// Ophthalmology-1988 Vol. 95 -P.l 515−1521
- Nugent RA, Belkin PI, Neigel JM et.al. Graves orbitopathy: correlation of CT and clinical findings //Radiology 1990 — Vol.177 — P. 675−682
- Nishida Y., Tian S., Isberg B. et al.// Arch. Clin.Exp.Ophthalmol. -2001-Vol.45-N.6-P.622−627.
- Nordyke RA, Gilbert Jr. FI. Optimal iodine-131 dose for eliminating hyperthyroidism in Graves' disease//J. Nucl. Med. -1995-Vol.32-P.411−416
- Pequegnat EP, Mayberry WE, McConahey WM & Wyse EP. Large doses of radioiodine in Graves' disease: effects on ophthalmopathy and long-acting thyroid stimulator //Mayo Clinic Proceedings -1967-Vol. 42-P.802−811.
- Perros P, Crombie A, Kendall-Taylor P. Natural history of thyroid-associated ophthalmopathy // Clin Endocrinol (Oxf). 1995-Vol.42 -P.45- 50.
- Perros P, Crombie AL, Matthews JN, Kendall-Taylor P. Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic//Clin Endocrinol (Oxf) -1993-Vol.38-P. 367−72.
- Peyster RG & Hoover ED Graves' orbitopathy. In Computerized Tomography in Orbital Diseases and Neuroopthalmology//Chicago: Year Book Medical Publisher-1984-Vol. 3-P. 97−114.
- Pinchera A, Bartalena L & Marcocci C. Therapeutic controversies. Radioiodine may be bad for Graves' ophthalmopathy, but... //Journal of Clinical Endocrinology and Metabolism-1995-Vol. 80-P.342−345.
- Scott I, Siatkowsky M. Thyroid eye disease // Semin Ophthalmol. 1999-Vol. 14-N. 2-P.52- 61.
- Sieradzky I, Katra B, Mirkiewiez-Sieradzka B. Czymmiki ryzyka wystapienia oftalmopatii w prsebiegy choroby Graves-Basedowa // Przegl. Lek. 2000 — Vol.57- N.6 — P. 321- 323.
- Sialberg P., Svensson A., Hessman O. Surgical Treatment of Graves Disease: Evidence-Based Approach//World J.Surg. -2008-Vol.32-P.1269−1277.
- Sridama V & DeGroot LJ. Treatment of Graves' disease and the course of ophthalmopathy//American Journal ofMedicine-1989-Vol. 87-P.70−73.
- Sridama V, McCormick M, Kaplan EL, Fauchet R, DeGroot LJ. Long-term follow-up study of compensated low-dose 1311 therapy for Graves' disease//N. Engl. J. Med. -1984—Vol. 311-P. 426−432
- Stassi G., De Mara R. Autoimmune thyroid disease-of cell death in autoimmunity //Nature Rev. Immunol.-2002-N. 3-P. 195−204.
- Shapiro B. Optimization of radioiodine therapy of thyrotoxicosis: what have we learned after 50 years? //J. Nucl. Med. -1993-Vol.34-P. 1638−1641
- Turner J, Sadler W, Brownlie B, Rogers T. Radioiodine therapy for Graves' disease: multivariate analysis of pretreatment parameters and early outcome//Eur. J. Nucl. Med. -1985-Vol. 11-P. 191−193.
- Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren J-G, Blomgren H et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group //New England Journal of Medicine -1992-Vol. 326-P. 1733−1738.
- Tallstedt L, Lundell G. Radioiodine treatment, ablation, and ophthalmopathy: a balanced perspective//Thyroid-1997-Vol. 7(2)-P. 241−5.
- Tallstedt L, Lundell G, Blomgren H & Bring J. Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment? //European Journal of Endocrinology -1994-Vol.l30-P. 494−497.
- Trokel L & Jacobiec FA. Correlation of CT scanning and pathologic features of opthalmic Graves' disease// Ophthalmology-1981 Vol. 88 — P. 553−564
- Teng W-P, Stark R, Munro AJ, Young SM, Boiysiewicz LK & Weetman AP. Peripheral blood T cell activation after radioiodine treatment for Graves' disease//Acta Endocrinologica-1990-Vol. 122-P. 233−240.
- Teshome T, Seyoum P. Thyroid ophthalmopathy of Graves' disease // Ethiop Med J. 2001- Vol.39- N. l- P. l- 8.
- Terwee CB, Gerding MN, Dekker FW, Prummer MF, Wiersinga WM. Development of disease-specific quality of life questionnaire for patients with Graves' ophthalmopathy: the GO-QOL// Br. J. Ophthalmol. -1998-Vol.82-P.773−779.
- Tuttle RM, Patience T & Budd S. Treatment with propylthiouracil before radioactive iodine therapy is associated with a higher treatment failure rate than therapy with radioactive iodine alone in Graves' disease//Thyroid— 1995—Vol. 5—P. 243−247.
- Utiger R. // Eur. J. Endocrinol. -1998 -Vol. 138-P. 368−370.
- Vestergaard P. Smoking and thyroid disorders—a meta-analysis//Eur. J. Endocrinol. -2002—Vol. 146-P. 153−61.
- Villanueva R., Inzerillo A., Tomer V. et al. Limited genetic susceptibility to severe Graves' ophthalmopathy: no role for CTLA-4 but evidence for an environmental etiology // Thyroid-2000-Vol. 10-N. 9-P. 791−798.
- Volpe R. Evidence that the immunosuppressive effects of antithyroid drugs are mediated through actions on the thyroid cell, modulating thyrocyte-immunocyte signaling: a review//Tbyroid —1994—Vol. 4—P. 217−223.
- Watson AB, Brownlie BE, Frampton CM, Turner JG, Rogers TG Outcome following standardized 185 MBq dose 1311 therapy for Graves' disease// Clin. Endocrinol. (Oxf) —1988—Vol. 28-P. 487−496
- Werner SC. Modification of the classification of the eye changes of Graves' disease. // Am. J. Ophthalmol. -1977. -Vol.83. P. 725−727.
- Weltman A., Wiersinga W. Current management of thyroidasso-ciated ophthalmopathy in Europe // Clin. Endocrinol. (Oxf.) -1998-Vol. 49-N. 1 -P. 11−12.
- Wiersinga W.M., Kahaly G.J. Graves' orbitopathy. A multidisciplinary approach. //Basel (Switzerland) -2007-P. 1−23.
- Wiersinga W, Bartalena L. Epidemiology and prevention of Graves' ophthalmopathy // Thyroid. 2002. — Vol.12. — N10. — P.855- 860.
- Yoshikawa K, Higashide T & Nakase Y Role of rectus muscle enlargement in clinical profile of dysthyroid ophthalmopathy// -1991 — Vol. 35 P. 175−181